Another larger scaled phase II clinical trial of Ervogastat with NASH is ongoing, aiming to assess the efficacy and safety of the inhibition of DGAT2 and ACC to resolve NASH with fibrosis (NCT04321031) [165]. The gene discussed is ACACA; the disease is metabolic dysfunction-associated steatohepatitis.